Understanding a drug’s mechanism of action (MOA) can greatly increase the likelihood of successful clinical trials by identifying biomarkers of patient response and providing a rationale for ...

Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

Dave Lahr, PhD, is currently leading the computational biology group at Foghorn Therapeutics, a biotech startup focused on treating diseases by correcting abnormal gene expression. In the early days ...

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist prescribed for weight loss, to reduce the risk of serious cardiovascular problems, and to treat a serious liver problem called ...

Biomarkers are key to the development of biological drugs, offering vital insights into drug mechanisms of action (MOA), informing clinical study design, and optimizing treatment strategies.

Over 12 million people worldwide suffer from a chronic infection with the hepatitis D virus. This most severe viral liver disease is associated with a high risk of dying from liver cirrhosis and liver ...

Merus N.V., an oncology-focused company, announced the publication of research on petosemtamab, a bispecific antibody targeting EGFR and LGR5, in the journal "Cancers." The study highlights the ...

Malaria represents one of the most serious threats to human health worldwide, and preventing and curing this parasitic disease still depends predominantly on the administration of a small number of ...

Conventional cancer drugs work by triggering apoptosis, that is programmed cell death, in tumor cells. However, tumor cells have the ability to develop strategies to escape apoptosis, rendering the ...